Cyclops Medtech with ENT and Neuro Healthcare Diagnosis gets $1M Funding from Unitus Ventures & Others

Forums Startups News (Startup) Cyclops Medtech with ENT and Neuro Healthcare Diagnosis gets $1M Funding from Unitus Ventures & Others

Viewing 0 reply threads
  • Author
    Posts
    • #24858
      TelegramGroup IoTForIndia
      Moderator
      • Topic 2519
      • Replies 0
      • posts 2519
        @iotforindiatggroup

        #News(Startup) [ via IoTForIndiaGroup ]


        Cyclops is significantly increasing access to diagnosis and timely treatment for the masses as well as reducing patients’ out-of-pocket expenses. BalanceEye’s scale-up is largely concentrated in tier 2, 3 and 4 cities including towns such as Morbi, Miraj, Islampur, Madurai, Trichy, Bargarh and Shillong. The product also has the ability to offer remote diagnosis, which augments clinical care in regions where physician availability is sparse and expands clinical reach.

        Bangalore-based Cyclops Medtech is revolutionizing the neuro-vestibular diagnostic space with a novel solution based on the established science of eye tracking. The startup recently raised $1 million from marquee VC firm Unitus Ventures and others to further augment its role as a leader in the space and rapidly scale up its installations base in India and rest of Asia. The round also saw participation of its earlier investor Mr. C P Bothra.

        Using eye tracking technology, Cyclops Medtech’s BalanceEye product has made diagnosis of various neuro-vestibular conditions easy and accurate and reduced the price to a fraction of that of existing imaging technologies. Dizziness and other symptoms of multiple neuro-vestibular disorders (including vertigo, migraine and balance) manifest in the pupil movement. Cyclops’ platform captures, measures and analyses these manifestations, helping clinicians determine their root cause in order to plan appropriate early stage treatment.

         


        Read More..

    Viewing 0 reply threads
    • You must be logged in to reply to this topic.